Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hunilife Biotechnology Inc. is navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units. HAUK TEODORO, PRICILA NMN is identified as the busiest examiner, with 1 busiest examiner pending action under their review. This distribution shows that each of the 2 pending office actions is assigned to a different examiner.
With 2 distinct art units involved, the portfolio demonstrates technical variety within its primary technology area. The 1 busiest examiner pending action represents a portion of the total 2 pending office actions for the company. Practitioners should prepare for 2 distinct examiner styles across these 2 distinct art units. This separation of the 2 pending office actions suggests that the company's current filings cover different technical sub-sectors. The involvement of 2 distinct examiners requires a coordinated strategy to ensure consistency across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701967 | METHODS TO REGULATE GLYCOLYSIS VIA TARGETING EXTRACELLULAR ALPHA-ENOLASE FOR TREATING HUMAN DISEASES | HAUK TEODORO, PRICILA NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998559 | DRUG CONJUGATES CONTAINING ALPHA-ENOLASE ANTIBODIES AND USES THEREOF | HAQ, SHAFIQUL | 72d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701967 | METHODS TO REGULATE GLYCOLYSIS VIA TARGETING EXTRACELLULAR ALPHA-ENOLASE FOR TREATING HUMAN DISEASES | HAUK TEODORO, PRICILA NMN | 1645 | §102§112 | Final Rejection | — | Pending | Apr 17, 2024 |
| 17998559 | DRUG CONJUGATES CONTAINING ALPHA-ENOLASE ANTIBODIES AND USES THEREOF | HAQ, SHAFIQUL | 1678 | §103 | Final Rejection | 72d | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial